New Needle-Free Epinephrine Powder Shows Rapid Absorption and Improved Stability

-

For decades, epinephrine auto-injectors have been the standard emergency treatment for anaphylaxis, although needle-free alternatives have recently emerged. Now, new clinical data released November 13, 2026, suggests that an experimental dry-powder nasal spray could offer rapid epinephrine absorption and improved medication stability compared with existing emergency treatments. Swedish pharmaceutical company Orexo AB announced new findings on OX640, an investigational epinephrine rescue medication designed to be administered through the nose without a needle.

The findings were presented by Orexo’s US subsidiary during the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona, held November 12–16, 2026. The company reported findings from two oral abstracts and a scientific poster examining how quickly the medication enters the bloodstream and how well its active ingredient withstands degradation over time.

Click to visit sponsor

A central focus of the research was how rapidly OX640 achieves potentially therapeutic epinephrine concentrations in the bloodstream. Dr Anne K Ellis, Professor and Chair of the Division of Allergy & Immunology at Queen’s University in Ontario and an advisor to Orexo, presented an analysis of the OX640-002 clinical study. Researchers measured the time required to reach epinephrine blood concentrations of 100 and 200 picograms per milliliter, as well as how long concentrations remained above those thresholds.

The results showed that OX640 reached these concentrations fastest under allergic rhinitis conditions, outperforming both normal nasal conditions and an intramuscular epinephrine injection in the comparisons reported. This finding is particularly encouraging because nasal inflammation could potentially affect how medications are absorbed through the nasal lining.

However, allergic rhinitis and anaphylaxis are distinct conditions, and the findings do not necessarily establish how OX640 would perform during an actual anaphylactic emergency. While rapidly achieving meaningful epinephrine blood concentrations is an important characteristic of emergency treatment, additional research is needed to determine how these results translate into clinical effectiveness.

Beyond absorption speed, researchers also examined the medication’s stability, an important consideration for emergency treatments that patients must carry and keep readily accessible. Orexo’s Chief Medical Officer, Dr Edward Kim, presented data comparing OX640 with a commercially available epinephrine autoinjector and a liquid epinephrine nasal spray.

After one year under accelerated aging conditions designed to evaluate medication stability, OX640 retained more than 98% of its active R-epinephrine potency. By comparison, the liquid nasal spray retained 66%, while the epinephrine autoinjector retained 55%. Although these findings suggest that the dry-powder formulation may offer advantages in resisting degradation, accelerated aging results do not directly establish how long the medication would remain effective under normal storage conditions.

Click to visit sponsor

Orexo attributes these characteristics to its proprietary AmorphOX® drug delivery technology, which is designed to improve medication stability while promoting rapid absorption through the nasal lining. The technology allows epinephrine to be formulated as a dry powder rather than a conventional liquid solution.

“These new data add to the growing body of evidence supporting OX640 as a differentiated, needle-free epinephrine rescue treatment,” said Nikolaj Sørensen, President and CEO of Orexo AB. “The combination of rapid epinephrine absorption and enhanced product stability addresses important attributes for an emergency treatment that needs to be readily available and reliable when patients need it most.”

For people living with severe food allergies, the prospect of another needle-free emergency treatment could be especially appealing. A medication that combines convenient administration with improved stability could potentially reduce some of the challenges associated with carrying emergency epinephrine.

Click to visit sponsor
Dave Bloom
Dave Bloomhttp://snacksafely.com
Dave Bloom is CEO and "Blogger in Chief" of SnackSafely.com.

Find Allergy-Friendly Products

Follow Us

51,195FansLike
12,912FollowersFollow
2,913FollowersFollow
623FollowersFollow
183SubscribersSubscribe